Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M.
Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
Eur J Heart Fail 2007;9:75-82.
Läs mer, länk till PubMed…
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M; SURVIVE Investigators.
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891.
Läs mer, länk till PubMed…
Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Am J Cardiol 2006;98:102-106.
Läs mer, länk till PubMed…
Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT.
Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
Heart 2006;92:1768-1772.
Läs mer, länk till PubMed…
Raja SG, Rayen BS.
Levosimendan in cardiac surgery: current best available evidence.
Ann Thorac Surg 2006;81:1536-1546.
Läs mer, länk till PubMed…
Follath F, Franco F, Cardoso JS.
European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
Am J Cardiol 2005;96:80G-85G.
Läs mer, länk till PubMed…
McLean AS, Huang SJ, Nalos M, Ting I.
Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
J Cardiovasc Pharmacol 2005;46:830-835.
Läs mer, länk till PubMed…
Nanas JN, Papazoglou P, Tsagalou EP, Ntalianis A, Tsolakis E, Terrovitis JV, Kanakakis J, Nanas SN, Alexopoulos GP, Anastasiou-Nana MI.
Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Am J Cardiol 2005;95:768-771.
Läs mer, länk till PubMed…
Labriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B.
Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery.
Int J Clin Pharmacol Ther 2004;42:204-211.
Läs mer, länk till PubMed…
Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study.
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
Lancet 2002;360:196-202.
Läs mer, länk till PubMed…
Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI; RUSSLAN Study Investigators.
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Eur Heart J 2002;23:1422-1432.
Läs mer, länk till PubMed…
Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ.
Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
J Am Coll Cardiol 2000;36:1903-1912.
Läs mer, länk till PubMed…
Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W.
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure.
Circulation 2000;102:2222-2227.
Läs mer, länk till PubMed…
